GeneDx (WGS) Stock Price, News & Analysis

Company Overview

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

Key Stats

• Today's Range: $102.97 to $108.41
• 50-Day Range: $64.04 to $108.35
• 52-Week Range: $28.86 to $117.75
• Volume: 417,351 shs
• Average Volume: 980,924 shs
• Market Capitalization: $3.00 billion
• P/E Ratio: 2,102.60
• Dividend Yield: N/A
• Price Target: $101.63
• Consensus Rating: Moderate Buy

GeneDx Stock Analysis - MarketRank™

GeneDx scored higher than 62% of companies evaluated by MarketBeat, and ranked 369th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

GeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

GeneDx has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 115.46%

Earnings Growth

Earnings for GeneDx are expected to grow by 115.46% in the coming year, from $0.97 to $2.09 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GeneDx is 2,102.60, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.88.

Price to Earnings Ratio vs. Sector

The P/E ratio of GeneDx is 2,102.60, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.75.

Price to Book Value per Share Ratio

GeneDx has a P/B Ratio of 10.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

13.98% of the float of GeneDx has been sold short.

Short Interest Ratio / Days to Cover

GeneDx has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GeneDx has recently decreased by 6.20%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GeneDx does not currently pay a dividend.

Dividend Growth

GeneDx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.98% of the float of GeneDx has been sold short.

Short Interest Ratio / Days to Cover

GeneDx has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GeneDx has recently decreased by 6.20%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.07

News Sentiment

GeneDx has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 22 news articles for GeneDx this week, compared to 10 articles on an average week.

Search Interest

8 people have searched for WGS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, GeneDx insiders have bought 168.63% more of their company's stock than they have sold. Specifically, they have bought $5,601,000.00 in company stock and sold $2,085,051.00 in company stock.

Percentage Held by Insiders

29.60% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

WGS Stock Analysis - Frequently Asked Questions

How have WGS shares performed this year?

GeneDx's stock was trading at $76.86 at the beginning of the year. Since then, WGS stock has increased by 36.8% and is now trading at $105.13.

How were GeneDx's earnings last quarter?

GeneDx Holdings Corp. (NASDAQ:WGS) issued its quarterly earnings data on Tuesday, July, 29th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.40. The firm had revenue of $102.69 million for the quarter, compared to analysts' expectations of $86 million. GeneDx had a net margin of 0.39% and a trailing twelve-month return on equity of 16.51%.
Read the conference call transcript.

When did GeneDx's stock split?

Shares of GeneDx reverse split on Thursday, May 4th 2023.The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are GeneDx's major shareholders?

Top institutional shareholders of GeneDx include William Blair Investment Management LLC (5.72%), Zweig DiMenna Associates LLC (2.05%), Geode Capital Management LLC (1.70%) and Jennison Associates LLC (1.39%). Insiders that own company stock include Casdin Capital, Llc, Keith A Meister, School Of Medicine At Mo Icahn, Opko Health, Inc, Kareem Saad, Richard C Pfenniger Jr, Richard C Pfenniger Jr, Jason Ryan, Isaac Ro, Karen Ann White, Kevin Feeley, Katherine Stueland and Richard Miao.
View institutional ownership trends.

How do I buy shares of GeneDx?

Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GeneDx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:WGS
• CIK: 1818331
• Web: sema4.com
• Phone: 800-298-6470
• Fax: N/A
• Employees: 1,200
• Year Founded: N/A

Price Target and Rating

• Average Price Target for GeneDx: $101.63
• High Price Target: $120.00
• Low Price Target: $80.00
• Potential Upside/Downside: -3.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.05
• Trailing P/E Ratio: 2,109.00
• Forward P/E Ratio: 108.56
• P/E Growth: N/A
• Net Income: -$52.29 million
• Net Margins: 0.39%
• Pretax Margin: 0.42%
• Return on Equity: 16.51%
• Return on Assets: 9.35%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 2.87
• Quick Ratio: 2.70

Sales & Book Value

• Annual Sales: $362.32 million
• Price / Sales: 8.29
• Cash Flow: $1.02 per share
• Price / Cash Flow: 103.44
• Book Value: $9.71 per share
• Price / Book: 10.84

Miscellaneous

• Outstanding Shares: 28,533,000
• Free Float: 20,087,000
• Market Cap: $3.00 billion
• Optionable: Optionable
• Beta: 2.02